Guardant Health, Inc.
GH Healthcare Diagnostics & Research
Guardant Health, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $982.0 million, up 32.9% from fiscal 2024. In the quarter to June 2026, revenue grew 44.3%, EPS fell 12.5%, free cash flow fell 5.46% and total debt rose 34.7%, each against the same quarter a year earlier. Revenue growth for five consecutive years; insiders bought in the last twelve months.
Follow GH
Guardant Health, Inc. (GH) P/E ratio
Guardant Health, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 31 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| GH Guardant Health, Inc. | n/m |
| CRL Charles River Laboratories International, Inc. compare | n/m |
| DGX Quest Diagnostics Incorporated compare | 24.6× |
| LH Labcorp Holdings Inc. compare | 26.2× |
| MEDP Medpace Holdings, Inc. compare | 35.6× |
| MTD Mettler-Toledo International, Inc. compare | 36.4× |
| ILMN Illumina, Inc. compare | 48.4× |
| RVTY Revvity Inc. compare | 72.7× |
| ICLR ICON PLC compare | 254× |
| Diagnostics & Research industry median | 35.6× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)